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Many central nervous system (CNS) diseases including stroke, spinal cord injury (SCI), and brain tumors are a significant cause of
worldwidemorbidity/mortality and yet do not have satisfying treatments. Cell-based therapy to restore lost function or to carry new
therapeutic genes is a promising new therapeutic approach, particularly after human iPSCs became available. However, efficient
generation of footprint-free and xeno-free human iPSC is a prerequisite for their clinical use. In this paper, we will first summarize
the current methodology to obtain footprint- and xeno-free human iPSC. We will then review the current iPSC applications in
therapeutic approaches for CNS regeneration and their use as vectors to carry proapoptotic genes for brain tumors and review
their applications for modelling of neurological diseases and formulating new therapeutic approaches. Available results will be
summarized and compared. Finally, we will discuss current limitations precluding iPSC from being used on large scale for clinical
applications and provide an overview of future areas of improvement. In conclusion, significant progress has occurred in deriving
iPSC suitable for clinical use in the field of neurological diseases. Current efforts to overcome technical challenges, including
reducing labour and cost, will hopefully expedite the integration of this technology in the clinical setting.
1. Introduction
Several diseases affecting the central nervous system (CNS)
including stroke, spinal cord injury (SCI), and brain tumors
remain the leading causes of mortality and morbidity in the
US and worldwide [1]. Current therapies are still not fully
successful in restoring the damaged tissue, in the case of
stroke and SCI, or in selectively killing tumor cells dispersed
in otherwise normal parenchyma, while sparing the latter,
in the case of brain tumors. Cell-based therapies offer the
potential advantages to provide regenerative tissue or to
provide “vectors” aimed at targeting diseased cells. One
additional challenge to improve therapies for CNS diseases
is a better understanding of their pathophysiology, partic-
ularly for neurodegenerative diseases, such as Parkinson’s
diseases [2] or amyotrophic lateral sclerosis (ALS) [3]. For
this purpose, information that can be derived from patient’s
specific cells offers a great tool to accelerate the understanding
of mechanisms at the base of these conditions, possibly
providing new therapeutic approaches.
The isolation of embryonic stem cells (ESC) was initially
considered the most innovative strategy to approach “cell-
based regenerative medicine” [4] due to their pluripotent
nature, their unrestricted power of self-renewal, and their
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ability to autodifferentiate into any cellular type. Unfortu-
nately, many aspects have limited their application in treating
human diseases, including ethical and technical issues, such
as their derivation from early-stage embryos and the immune
rejection for nonautologous cell lines [5]. Subsequently, the
elaboration of “nuclear cloning” [6] or mammalian somatic
cell nuclear transfer seemed to solve some of these limitations
by creating a cloned cell from which to isolate the nuclear
transfer-derived ESC, as autologous donor cells for therapy.
This strategy demonstrated feasibility in a mouse model of
immunodeficiency [7] but was not successfully reproduced
in humans.
In 2006, Takahashi and Yamanaka [8] developed a line
of induced pluripotent stem cells (iPSCs) using fibroblasts.
They identified 24 candidate genes highly expressed in ESC
critical to confer andmaintain pluripotency.These geneswere
introduced into the mouse fibroblasts by a retroviral vector,
demonstrating the reprogramming of somatic cells back to
an ESC-like pluripotent state. iPSCs were first induced by
the transfer of only four genes [9], Oct4, Sox2, Klf4, and c-
Myc. This approach was applied to adult human fibroblasts,
leading to the creation of human iPSC [10]. Due to the
potential genomic integration of transgenes resulting from
the use of retroviruses containing the oncogene c-Myc, the
original technique carried a significant risk of tumorigenesis.
Recent improvements in nuclear reprogramming have made
iPSC induction safer as genes transfer can be achieved
with techniques other than viral transduction [11–14], thus
eliminating the risk of genomic integration. This is clinically
significant when iPSCs are considered for transplant, as they
represent a promising tool for regenerative medicine, in
pathologies such as cardiomyopathies [15], stroke [16], and
SCI [17].
The main characteristic of iPSC is pluripotency [18],
defining the ability to differentiate into three germ layers
and all cell types. The advantage of patient-specific iPSC is
twofold. In disease modelling, the effects of patient-relevant
mutations can be studied in the correct genetic and cellular
background. In cells-based therapy, patient-specific iPSCwill
obviate the needs of immune suppressors. The elaboration
of disease-derived iPSC [19] was first obtained in 2008
from a patient with ALS. These patient-specific iPSCs were
successfully directed to differentiate intomotor neurons, rep-
resenting a potentially novel platform for disease modelling.
Advances in induction of patient-specific iPSCs allowed their
use tomodel a widespread variety of patient-specific diseases,
such as cardiomyopathies [16] and as recently reported
chemotherapy induced neurotoxicity [20].
Finally, iPSC-derived cells can be used in cell-based
therapy as vectors to carry genes to their original organ. This
has been explored for brain tumors using ESC and NPC
[21, 22]. The rationale for this approach relies on the fact
that primary brain tumors are very aggressive, infiltrative,
and invasive, thus requiring cell-based therapy that can target
tumoral cells while sparing the normal brain [22].
To accomplish the goals of using iPSC in large scale,
numerous technical advances need to be pursued including
reducing labour and cost to produce iPSC in large scale. In
2009 in the US, the FDA approved the country’s first human
trial on ESC transplantation into patients suffering from SCI;
the trial, however, came to a halt in November 2011 when the
company financing the trial announced the discontinuation
of the trial due to financial issues [23]. Additionally, iPSC
should be “safe” and easily obtainable from body sources
with minimal invasiveness and high efficiency of reprogram-
ming, overcoming three major current obstacles. First, the
risk of genomic modification due to viral transgenes needs
to be overcome by insertion-free or “footprint-free” iPSC.
Second, the risk of teratogenicity if undifferentiated iPSCs
are engrafted requires full differentiation or reprogramming
inactivation of iPSCs before transplant. Finally, the risks
of transmission of nonhuman pathogens to humans and/or
immune response concern triggered by contamination from
nonhuman antigens, deriving from the xeno-cell-dependent
culture systems, necessitate the development of xeno-free
iPSCs. Techniques and results used to overcome these bur-
dens are described below.
2. Methods
Figure 1 summarizes methods to obtain iPSC. Different
somatic cells can be used for reprogramming (Figure 1, left
column). Reprogramming techniques (Figure 1, center col-
umn) first used viral based genomic integration (Figure 1(a))
and then used footprint-free techniques (Figure 1(b)). Finally,
culturing conditions (Figure 1, right column) at first requiring
feeder cells evolved to xeno-free conditions to allow safer
clinical translation. Methodologies summarized in the dia-
gram are briefly reported below.
2.1. Reprogrammable Somatic Cells for iPSC. Ideally, cell
sources of hiPSC should be acquired easily and noninvasively
from patients and should be reprogrammed into iPSCs with
high efficiency. Cell types successfully utilized for hIPSC
production include dermal fibroblasts [10], bone marrow
CD34+ cells [32], cord blood cells [33], peripheral blood cells
[34], adipose-derived stromal cells [35], neural stem cells
[36], and keratinocytes [37] (Figure 1, left column).
Recently, Nakagawa et al. [38] were able to obtain an
adequate number of footprint-free, xeno-free hiPSC clones
from both skin-derived fibroblasts and blood cells. Lee et al.
[39] reported a method to generate footprint- and xeno-free
iPSC from urine cells which can be obtained totally non-
invasively using extracellular matrix-based xeno-free iPSC
culture condition and episomal transfection.
2.2. “Footprint-Free” iPSC. The reprogramming of somatic
cells to pluripotency implicates the risk of genomic mod-
ification when retroviral and lentiviral vectors are used.
Indeed, although these vectors are feasible and efficient in
iPSC production, they also cause insertional mutagenesis
due to viral vector integration, prompting caution with their
translation to clinical applications (Figure 1(a)).
Among the first attempts to produce footprint-free iPSC
was the use of nonintegrating vectors encoding reprogram-
ming factors (RF) based on adenovirus [40] and transient
plasmid to be repeatedly transfected [41, 42]. However, this
resulted in much lower reprogramming efficiency with still
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Figure 1: Diagrammatic representation of methods used to obtain human iPSC. Different somatic cells can be used for reprogramming (left
column). Reprogramming techniques (center column) first used viral based genomic integration (a) and then used footprint-free techniques
(b). Footprint-free iPSC induction can be obtained by Sendai virus (b(i)); episome (b(ii)); mRNA (b(iii)); siRNA (b(iv)). Finally, culturing
conditions (right column) at first requiring feeder cells evolved to xeno-free conditions to allow safer clinical translation.
some residual risk of genomic alteration, thus necessitating
PCR screening of iPSC colonies or sequencing before taking
them forward to clinical application.
Another intriguing system is represented by episomes
(Figure 1(b(ii))) [43, 44] where the expression vector is
circular DNA encoding RF that is incorporated by cells
through penetrating peptide moieties in culture media. The
episomes show rapid and persistent RF expression, allowing
a single transfection procedure to obtain iPSC, while they
are lost by dilution over several weeks [45]. Nonetheless,
episome-derived iPSCs need to be checked for genomic
recombination and successful clearance of the RF, making
their clinical applicability far from optimal.
Later on, new attracting methods to generate footprint-
free iPSCs with higher reprogramming efficiency were devel-
oped: the RNA virus (Figure 1(b(i))), Sendai virus (SeV)
[46], and mRNA or modified RNA (modRNA) [47] (Fig-
ure 1(b(iii))). In the SeV, RNA systemRF are infected into cells
by using a recombinant animal virus with a completely RNA-
based replication cycle. Robust iPSC colonies are generated in
2-3 weeks, with efficiency even higher than the conventional
retroviral and lentiviral protocols. As with the episomal
method, the SeV RNA has the “one-shot” advantage and
is lost from the iPSC between expansion passages. With
the exception of the genomic recombination risk, SeV RNA
method encounters the same concerns of episomal system
for the clinical application, that is, the passive clearance of
RF and false negative results. The mRNA method has been
successfully applied in iPSC field, achieving high efficiency
and rapid kinetics, without risk of accidental insertional
mutagenesis and without the need for multiple passages to
clear residual vector traces (Figure 1(b(iii))). Indeed, once
transfection of RF is completed, ectopic expression in the
cells soon ceases thanks to the rapid degradation of mRNA
in the cytoplasm. Synthetic mRNA delivery to cells can occur
by electroporation allowing diffusion into the cytoplasm by
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Figure 2: Human iPSC can be differentiated into all cell lineages.
creating pores in the cell membrane [48] and by complexing
the RNA with cationic vehicles permitting internalization
by endocytosis after the linkage to the negatively charged
cell membrane [49]. Moreover, parallel to mRNA transfect
other RNAs (siRNA, miRNA, and long noncoding RNA)
can be codelivered with the same method, increasing the
possibilities to control reprogramming and differentiation by
supplying growth factors, cytokines, and small molecules in
culture media [50] (Figure 1(b(iv))).
2.3. Xeno-Free iPSC. Another important safety-related issue
to translate iPSC into the clinical setting is the need to reduce
or eliminate the use of animal-derived materials, establishing
xeno-free conditions for both iPSC derivation and expansion
(Figure 1, right column).
All the initial culturing techniques for hiPSC utilized
mouse embryonic fibroblast feeder cells and media contain-
ing other xeno-contaminated reagents, inheriting protocols
developed for hESC cells over the last decade. The mouse
feeder cell system bears in itself the risk of transmission of
nonhuman pathogens to humans as well as immunological
issues of rejection triggered by nonhuman antigens [50].
To overcome these obstacles, several protocols have been
attempted. Almost all the approaches are based on media
optimization toward xeno-free conditions and on the use
of extracellular matrix- (ECM-) based feeder-independent
culture system [50], substituting the routine system that
includes bovine serum albumin (BSA) on Matrigel. Various
matrices can be used to replace feeder cells, such as Matrigel,
CELLstart, recombinant proteins, and synthetic polymers.
Xeno-free media recently developed include TeSR2 and
Essential E8 medium [39].
The former, developed by Sun et al. [51] for hESC
culturing, is characterized by the complete absence of animal
proteins and the inclusion of human serum albumin and
human sourced matrix proteins. However, the prohibitively
expensive costs of these media make their use not applicable
for routine use. Additionally, the high variability of human
serum albumin from batch to batch can impact the repro-
gramming results. When it was clarified that the need of
albumin in ES and iPSCmedia is strictly linked to prevent the
toxicity of another component, 𝛽-mercaptoethanol (BME),
contained in the media, and is no longer necessary when
BME is removed, a new medium was proposed, defined
as E8 (eight components, including the DMEM/F12) [52].
Additionally, surfaces that efficiently support derivation and
maintenance of hESC and iPSC were added such as laminin,
vitronectin, and fibronectin purified from human plasma,
or pericellular matrix of decidua-derived mesenchymal stem
cells [52]. Several vitronectin variants were tested and in
particular VTN-NC and VTN-N resulted to be efficient [40].
Nakagawa et al. [38] reported that recombinant laminin-
511 E8 fragments are useful matrices for maintaining hESCs
and footprint-free hiPSCs when used in combination with
the StemFitTM medium, completely xeno-free. Their study
showed that the Ff-hiPSCs established under footprint-free
and xeno-free conditions from several types of somatic cells
are similar to the hiPSCs established using the conventional
systemwith feeders, showing equivalent growth and differen-
tiation potential.
2.4. hiPSCDifferentiation. hiPSC, obtainedwith themethods
above, can be differentiated into all cell lineages as shown in
Figure 2. Detailed protocols on how to differentiate footprint-
free hiPSC were previously reported [16, 53].
3. Results
3.1. iPSC and Ischemic Stroke. Ischemic stroke, still causing
high disability and mortality, prompted the investigation
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of therapeutic approaches other than thrombolytic therapy
and/or percutaneous intravascular interventions [54]. iPSCs
have emerged as a promising tool for cell replacement in
ischemic brain injuries. At least 4 synergistic mechanisms
have been proposed to account for the beneficial effect of stem
cells on experimental stroke: neuroprotection, neurogenesis,
modulation of the immune response, and angiogenesis. The
first [55] occurs by secretion of neuroprotective cytokines
such as VEGF and NGF and neurotrophins and by causing
paracrine effects, increasing dendritic plasticity and axonal
rewriting. Endogenous neurogenesis [56] has been shown
by increased number of cells expressing the early neu-
ronal lineage marker Dcx in murine models. Modulation
of immune and inflammatory response [57] is achieved by
reducing the main inflammatory regulators in focal brain
tissue, such as microglia, by inducing the downregulation
of some inflammatory regulators, such as TNF-alpha, IL-6,
and leptin receptors. Finally, angiogenesis [58] is stimulated
with formation of brainmicrovessels and functional recovery
has been demonstrated in peri-infarct regions after stem cell
infusion in rat stroke model.
3.2. iPSC and SCI. SCI can be caused by a variety of
factors, such as trauma, ischemia, and iatrogenic injury,
resulting in sensory and motor dysfunctions. SCI [59] is
the consequence of the primary irreversible damage caused
by direct mechanical insult and the secondary injuries of
trauma as inflammatory/immune response, cell necrosis
and/or apoptosis, excitotoxins, oxygen free radical, ionic
imbalance, and axon reaction.The therapeutic effects of iPSC
in SCI can affect multiple mechanisms [60], such as the
reconstruction of neural synaptic connections by neural cells
derived by iPSC, axons remyelination by oligodendrocytes,
and the neuroprotection due to neurotrophic factors secreted
by neural cells. In mouse SCI model, data show that treating
the damage with iPSC could restore the impaired func-
tion through these mechanisms [61]. Mouse iPSC-derived
NPC transplanted into nonobese diabetic-severe combined
immunodeficiency (NOD-SCID) mice’s spinal cord 9 days
after SCI differentiated into all three neural lineages did not
give rise to teratoma and showed their neural differentiation
capacity, participating in remyelination and inducing the
axonal regrowth and promoting motor functional recovery
[62]. Thus, iPSC clone-derived NPC may be a promising cell
source for future transplantation therapy in SCI.
3.3. iPSC and Neurodegenerative Disease Modelling. Patient-
specific iPSCs provide the unprecedented opportunity to
study insights and potentially develop therapeutic options
for neurodegenerative diseases, up to date difficult to target
due to lack of experimental models. The generation of cell
models of diseases is based on the differentiation of disease-
specific iPSC into cell types relevant to the diseases [63]. The
characterization of iPSC from patient-specific fibroblasts has
been reported [64].
Table 1 summarizes the CNS disease-specific iPSCs that
have been derived. Most diseases in which the phenotype
could be recapitulated were congenital and paediatric disor-
ders [63].
3.4. iPSC and Adrenoleukodystrophy Modelling. Jang et al.
[24] generated X-linked adrenoleukodystrophy (ALD) iPSC,
for both childhood cerebral ALD (CCALD) and adreno-
myeloneuropathy (AMN). Both CCALD and AMN iPSC
normally differentiated into oligodendrocytes, the cell type
primarily affected in the X-linked ALD brain, indicating
no developmental defect due to the ABCD1 mutations.
Although low in X-ALD iPSC, very long chain fatty acid
(VLCFA) level was significantly increased after oligodendro-
cyte differentiation. VLCFA accumulation was much higher
in CCALD oligodendrocytes than AMN, indicating that the
severe clinical manifestations in CCALDmight be associated
with abnormal VLCFA accumulation in oligodendrocytes.
Furthermore, the abnormal accumulation of VLCFA in the
X-ALD oligodendrocytes can be reduced by the upregulated
ABCD2 gene expression after treatment with lovastatin or
4-phenylbutyrate. X-ALD iPSC model recapitulates the key
events of disease pathophysiology, as VLCFA accumulation
in oligodendrocytes, and allows for early diagnosis of the
disease subtypes. X-ALD oligodendrocytes can be a useful
cell model system to develop new therapeutics for treating X-
ALD.
3.5. iPSC and Rett SyndromeModelling. Using Rett syndrome
(RTT) as an autism spectrum disorders genetic model,
Marchetto et al. [28] developed a culture system using iPSC
from RTT patients’ fibroblasts, generating functional neu-
rons. Neurons derived from RTT-iPSC had fewer synapses,
reduced spine density, smaller soma size, altered calcium
signalling, and electrophysiological defects. Finally, they used
RTT neurons to test the effects of drugs in rescuing synaptic
defects. Their model recapitulates early stages of a human
neurodevelopmental disease.
3.6. iPSC and Familial Dysautonomia Modelling. Familial
dysautonomia (FD) is a rare but fatal peripheral neuropathy,
characterized by the depletion of autonomic and sensory
neurons and caused by a point mutation in the IKBKAP gene,
involved in transcriptional elongation. Lee et al. [27] elab-
orated the patient-specific FD-iPSCs and evidenced tissue-
specific missplicing of IKBKAP in vitro by performing gene
expression analysis in purified FD-iPSC-derived lineages.
Patient-specific neural crest precursors express particularly
low levels of normal IKBKAP transcript, as a mechanism for
disease specificity. They also validated the potency of candi-
date drugs in reversing aberrant splicing and ameliorating
neuronal differentiation. Finally, Koch et al. [30] illustrate
that iPSCs enable the study of aberrant protein processing
associated with late-onset neurodegenerative disorders in
patient-specific neurons in Machado-Joseph disease model.
3.7. iPSCs as Gene Therapy Vectors for Brain Tumors. High
grade gliomas (HGG), the most common primary brain
tumors, remain a clinical challenge with an average life
expectancy of 14months for themost aggressive type after the
best surgical, radiation, and chemotherapy treatments [65]
due to the tumors’ ability to diffusely invade and infiltrate
the brain parenchyma. This coupled with the inability of
most therapeutic compounds to penetrate the brain due to
the blood-brain barrier raises the need to develop vectors
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Table 1: Neurodegenerative specific iPSC for disease modelling.
CNS disease Genetic defect Phenotype
Adrenoleukodystrophy [24] ABCD1 Increased level of VLCFA in oligodendrocytes
Alzheimer’s disease [25]
Presenilin 1
Presenilin 2
APP duplication
Increased amyloid 𝛽 (A𝛽) secretion
Increased A𝛽40 production
Increased phosphor-tau and GSK-3𝛽 activity
Amyotrophic lateral
sclerosis [3]
SOD1, VAPB, and
TDP43
Decreased VAPB in motor neurons
Elevated levels of TDP43 protein
Huntington’s disease [26] CAG repeat expansionin HTT gene Enhanced caspase activity upon growth factor deprivation
Familial dysautonomia [27] IKBKAP Decreased expression of genes involved in neurogenesis and neural differentiation
Parkinson’s disease [3] LRRK2, PINK1, andSNCA
Impaired mitochondrial function in PINK1-mutated dopaminergic neurons
Increased sensitivity to oxidative stress in LRRK2 and SNCA-mutant neurons
Rett syndrome [28] MeCP2CDKL5
MeCP2: neuronal maturation defects, decreased synapse number
CDKL5: aberrant dendritic spines
Spinal muscular atrophy
[29] SMN1 Decreased size, number, and survival of motor neurons
Machado-Joseph disease
[30] MJD1 (ATXN3) Excitation-induced ataxin-3 aggregation in differentiated neurons
Schizophrenia [31] Multifactorial Reduced neuronal connectivity, increased consumption in extramitochondrialoxygen, and elevated levels of ROS
VLCFA: very long chain fatty acid; ROS: reactive oxygen species.
Table 2: Therapeutic agents delivered by SC for the treatment of HGG.
Agent delivered Type of stem cells
ESC NSC MSC
Cytokines Mda-7/IL24, TRAIL IL-4, IL-12, IL-23, TRAIL +/− BMZ,and S-TRAIL +/−MIR/TMZ
IL-2, IL-12, IL-18, INF𝛼, INF-𝛽, and TRAIL +/−
PI3KI
Enzyme/prodrug Tk/GCV, CD/5FC +/− IFN𝛽 Tk/GCV
Viral particles Mutant HSV-1, CRAd-survivin CRAd-survivin, CRAd-CXCR4, and CRAd-Rb
Metalloproteinases PEX
Antibodies EGFRvIII
Nanoparticles Ferrociphenol lipid
that can infiltrate the brain in a fashion similar to glioma
tumor cells delivering proapoptotic genes that spare normal
parenchyma. Stem cells (SC) seem to be a logical choice as
they maintain migratory capacity after transplant into the
brain [66]. Table 2 summarizes the SC used as vectors to
deliver specific therapeutic agents for HGG. Thus far, three
types of SC have been tested as vehicle for therapeutic agents
in brain tumors: ESC, mesenchymal SC (MSC), and NPC.
Each strategy has specific advantages and disadvantages.
ESC can be permanently and genetically modified using
homologous recombination [67], but their use is held back
by ethical and regulatory issues. NPC are the only SC native
to the brain [68]; they have tumor tropism and infiltrative
capacity across the blood-brain barrier; however, they are
difficult to harvest and have risk of dedifferentiation with
potential for tumorigenesis. MSC are easily obtainable from
bone marrow and peripheral tissues or blood cells, but a
major limitation is safety, due to the risk of promoting the
growth potential of HGG cells [69]. Our published work
shows that mESC-derived astrocytes maintain migration
capacity after implant into the brain and in the presence of
brain tumors they “home” within and around it [70]. We
have also shown that a proapoptotic gene can be inserted
prior to ECS differentiation into astrocytes downstream to
a tetracycline inducible promoter (“tet-on”) to regulate its
expression with administration of doxycycline (Dox) [71].
Additionally, we have shown the proapoptotic effects of the
mECS-derived astrocytes expressed gene in vitro and in vivo
[72, 73]. Whereas most of the work using stem cells as
vector is done on experimental models, there is a current
FDA-approved phase 1 clinical trial using NPC engineered
to convert the 5FU prodrug into active chemotherapy [74].
However, there are at least 4 significant limitations to this
vector: (1) NPC are difficult to obtain and must be derived
from fetal brain raising technical and ethical questions; (2)
NPC are not fully differentiated and therefore are potentially
tumorigenic; (3) viral vectors, used to engineer NPC, cause
significant risk of insertional mutagenesis; (4) NPC are not
autologous requiring potential immunosuppressive therapy.
This prompted us to explore other vectors, such as iPSC.
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Figure 3: Microphotographs of footprint-free iPSC-derived astrocytes. (a) Phase contrast and (b) immunocytochemistry for GFAP 9 days
after MACS sorting of mRNA iPSC-derived astrocytes.
We have shown that we can differentiate astrocyte from
iPSC in similar fashion to those obtained from ESC [21].
Recently, we have also shown that we can differentiate a
pure population of footprint-free iPSC-derived astrocytes
(Figure 3), which does not cause teratogenicity after implant
into the brain [53].We therefore propose that patient-specific
cells can be reprogrammed into “footprint-free” hiPSC, their
DNA engineered to carry proapoptotic genes, and then be
differentiated into astrocytes and reimplanted in the same
patient at the time of surgery for brain tumor recurrence
(Figure 4). As discussed below, the ability to translate these
exciting data to the clinical setting is still halted by technical
obstacles, cost-effectiveness, and scalability.
4. Discussion
Human SC represent important cell resources and hold high
promise for disease modelling, cell-based therapies, and
drug and pharmaceutical applications [75]. iPSCs are the
most appealing among SC due to the recent advances in
reprogramming footprint-free and xeno-free iPSC [53].They
are a promising platform to pave the way for personalized
medicine as they can be differentiated from the same patient
to study his/her disease and/or response to new drugs and/or
delivered back carrying proapoptotic genes/drugs. Current
limitations, however, are still halting the translational use of
hiPSC and need additional technical improvements. These
are limited to not only the reprograming process, such as
genetic/epigenetic abnormalities and immunogenicity, but
also cost and labor of reprogramming process.
Genetic and epigenetic abnormalities may be reduced
during reprogramming by improving efficiency to a level
where iPSC could be derived without colony picking and
colonial expansion, because the low efficiency and slow
kinetics of iPSCs generation may give rise to the activation
of cell growth pathways and suppression of tumor suppressor
pathways. Therefore, using epigenetic small molecules to
improve reprogramming efficiency could represent the key
to ensure greater iPSCs safety. Reprogramming with mRNA
could be highly immunogenic [76], since human cells have
antiviral defence pathways triggered by exogenous RNA.
These pathways can activate the suppression of translation,
the degradation of foreign transcripts, and the priming of
cytostatic and apoptotic pathways. To avoid such immuno-
genic response, several strategies have been tested, such as
the incorporation of modified nucleobases (pseudouridine)
into synthetic transcripts [77] or the supplementation of
cell media with an extracellular decoy receptor for type I
interferons [78] that blunt immune responses to infection.
A major obstacle in using iPSCs for clinical application
resides in the risk of genomic modification when they
are derived with viral transgenes, but the generation of
“footprint-free” iPSC-derived astrocytes represents a promis-
ing innovation. Nonetheless, some drawbacks still exist even
with mRNA reprogramming. First, certain cell types, includ-
ing blood cells, are difficult to transfect [79]. Secondly, the
approach works robustly if mRNA is transfected at frequent
intervals to yield a steady state of protein expression over
time. Cationic transfection reagents come to aid since they are
well tolerated on repeat administration, while electroporation
procedures are less feasible.
To achieve their full clinical and commercial poten-
tial, significant challenges must be overcome in order to
produce iPSC-derived cells at commercially relevant scale.
These include operational performances, economics, qual-
ity control and compliance, safety, and flexibility. Recent
innovations in integrated bioprocesses design are helpful in
improving hiPSC expansion.These include planar and three-
dimensional culture systems. In particular, planar processing
platforms are important for the production of autologous
and patient-specific hiPSC-derived cells that necessitate a
scale-out rather than a scale-up process [80]. Additional
improvements are needed in the differentiation processes,
including planar strategies and bioreactor-based systems.
Finally, shorter reprogramming process and strategies to
rapidly induce iPSC need to be developed as well as media
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(a) Bone marrow cells removed from patient
(c) Tumor cells killer gene added to the stem cells
(d) Engineered cells cloned
(b) Ribonucleic acid added to the cells, which
turns them into stem cells
(e) Engineered cells transformed to brain cells and implanted back
in the same patient during brain surgery
Figure 4: Personalizedmedicine using patient-specific iPSC. Diagrammatic summary of reprogramming patient-specific cells into footprint-
free hiPSC, engineering their DNA to carry proapoptotic genes, differentiating them into astrocytes, and reimplanting them at the time of
surgery for brain tumor recurrence. (a) Dermal fibroblast cells obtained from patient. (b) Ribonucleic acid (RNA) added to cells, which turns
them into stem cells. (c) Tumor cells killer gene added to stem cells. (d) Engineered cells cloned. (e) Engineered cells transformed to brain
cells, astrocytes, and implanted back in the same patient at the time of surgical resection for recurrent tumor.
to improve iPSC efficiency without causing any aberrations
of reprogrammed cells [81].
5. Conclusion
iPSCs provide a novel platform for CNS regenerative
medicine, neurodegenerative disease modelling, pharmaceu-
tical testing, and brain tumor treatments with a personalized
medicine paradigm. The unique properties of iPSCs to self-
renew and to differentiate into cells of three germ layers make
them an invaluable tool for the present and the future of
most neurologic disorders. Technical improvements in repro-
gramming with high efficiency induction systems and virus-
free and integration-free strategies have greatly advanced
iPSC therapeutic potentials. Additional efforts focused on
refining reprogramming approaches will further enhance
their clinical applications. Current efforts to reduce labour
and cost are also instrumental for the integration of iPSC and
iPSC-derived cells in the clinical setting.
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